|
1
|
Kopp P: Resveratrol, a phytoestrogen found
in red wine. A possible explanation for the conundrum of the
'French paradox'? Eur J Endocrinol. 138:619–620. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta
RG, et al: Cancer chemopreventive activity of resveratrol, a
natural product derived from grapes. Science. 275:218–220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhat KPL, Kosmeder JW II and Pezzuto JM:
Biological effects of resveratrol. Antioxid Redox Signal.
3:1041–1064. 2001. View Article : Google Scholar
|
|
4
|
Virgili M and Contestabile A: Partial
neuroprotection of in vivo excitotoxic brain damage by chronic
administration of the red wine antioxidant agent, trans-resveratrol
in rats. Neurosci Lett. 281:123–126. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Athar M, Back JH, Tang X, Kim KH,
Kopelovich L, Bickers DR and Kim AL: Resveratrol: A review of
preclinical studies for human cancer prevention. Toxicol Appl
Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carter LG, D'Orazio JA and Pearson KJ:
Resveratrol and cancer: Focus on in vivo evidence. Endocr Relat
Cancer. 21:R209–R225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clément MV, Hirpara JL, Chawdhury SH and
Pervaiz S: Chemopreventive agent resveratrol, a natural product
derived from grapes, triggers CD95 signaling-dependent apoptosis in
human tumor cells. Blood. 92:996–1002. 1998.PubMed/NCBI
|
|
8
|
Tessitore L, Davit A, Sarotto I and
Caderni G: Resveratrol depresses the growth of colorectal aberrant
crypt foci by affecting bax and p21(CIP) expression.
Carcinogenesis. 21:1619–1622. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ding XZ and Adrian TE: Resveratrol
inhibits proliferation and induces apoptosis in human pancreatic
cancer cells. Pancreas. 25:e71–e76. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aziz MH, Nihal M, Fu VX, Jarrard DF and
Ahmad N: Resveratrol-caused apoptosis of human prostate carcinoma
LNCaP cells is mediated via modulation of phosphatidylinositol
3′-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther.
5:1335–1341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang HY, Shih A, Cao HJ, Davis FB, Davis
PJ and Lin HY: Resveratrol-induced cyclooxygenase-2 facilitates
p53-dependent apoptosis in human breast cancer cells. Mol Cancer
Ther. 5:2034–2042. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB,
Yang K, Shen HF and Xie LP: Resveratrol induces apoptosis and cell
cycle arrest of human T24 bladder cancer cells in vitro and
inhibits tumor growth in vivo. Cancer Sci. 101:488–493. 2010.
View Article : Google Scholar
|
|
13
|
Nakagawa H, Kiyozuka Y, Uemura Y, Senzaki
H, Shikata N, Hioki K and Tsubura A: Resveratrol inhibits human
breast cancer cell growth and may mitigate the effect of linoleic
acid, a potent breast cancer cell stimulator. J Cancer Res Clin
Oncol. 127:258–264. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joe AK, Liu H, Suzui M, Vural ME, Xiao D
and Weinstein IB: Resveratrol induces growth inhibition, S-phase
arrest, apoptosis, and changes in biomarker expression in several
human cancer cell lines. Clin Cancer Res. 8:893–903.
2002.PubMed/NCBI
|
|
15
|
Shih A, Davis FB, Lin HY and Davis PJ:
Resveratrol induces apoptosis in thyroid cancer cell lines via a
MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab.
87:1223–1232. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roman V, Billard C, Kern C, Ferry-Dumazet
H, Izard JC, Mohammad R, Mossalayi DM and Kolb JP: Analysis of
resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br
J Haematol. 117:842–851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang YC, Tsai SH, Chen L, Lin-Shiau SY
and Lin JK: Resveratrol-induced G2 arrest through the inhibition of
CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem
Pharmacol. 65:1053–1060. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liao PC, Ng LT, Lin LT, Richardson CD,
Wang GH and Lin CC: Resveratrol arrests cell cycle and induces
apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med
Food. 13:1415–1423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park JW, Choi YJ, Suh SI, Baek WK, Suh MH,
Jin IN, Min DS, Woo JH, Chang JS, Passaniti A, et al: Bcl-2
overexpression attenuates resveratrol-induced apoptosis in U937
cells by inhibition of caspase-3 activity. Carcinogenesis.
22:1633–1639. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wolter F, Akoglu B, Clausnitzer A and
Stein J: Downregulation of the cyclin D1/Cdk4 complex occurs during
resveratrol-induced cell cycle arrest in colon cancer cell lines. J
Nutr. 131:2197–2203. 2001.PubMed/NCBI
|
|
21
|
Gao X, Xu YX, Divine G, Janakiraman N,
Chapman RA and Gautam SC: Disparate in vitro and in vivo
antileukemic effects of resveratrol, a natural polyphenolic
compound found in grapes. J Nutr. 132:2076–2081. 2002.PubMed/NCBI
|
|
22
|
Mouria M, Gukovskaya AS, Jung Y, Buechler
P, Hines OJ, Reber HA and Pandol SJ: Food-derived polyphenols
inhibit pancreatic cancer growth through mitochondrial cytochrome c
release and apoptosis. Int J Cancer. 98:761–769. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mahyar-Roemer M, Katsen A, Mestres P and
Roemer K: Resveratrol induces colon tumor cell apoptosis
independently of p53 and precede by epithelial differentiation,
mitochondrial proliferation and membrane potential collapse. Int J
Cancer. 94:615–622. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang C, Ma WY, Goranson A and Dong Z:
Resveratrol suppresses cell transformation and induces apoptosis
through a p53-dependent pathway. Carcinogenesis. 20:237–242. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuo PL, Chiang LC and Lin CC: Resveratrol-
induced apoptosis is mediated by p53-dependent pathway in Hep G2
cells. Life Sci. 72:23–34. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baur JA: Biochemical effects of SIRT1
activators. Biochim Biophys Acta. 1804:1626–1634. 2010. View Article : Google Scholar :
|
|
27
|
Sakata K, Kondo T, Mizuno N, Shoji M,
Yasui H, Yamamori T, Inanami O, Yokoo H, Yoshimura N and Hattori Y:
Roles of ROS and PKC-βII in ionizing radiation-induced eNOS
activation in human vascular endothelial cells. Vascul Pharmacol.
70:55–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inoue S, Arai N, Tomihara K, Takashina M,
Hattori Y and Noguchi M: Extracellular Ca(2+)-dependent enhancement
of cytocidal potency of zoledronic acid in human oral cancer cells.
Eur J Pharmacol. 761:44–54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taguchi K, Sakata K, Ohashi W, Imaizumi T,
Imura J and Hattori Y: Tonic inhibition by G protein-coupled
receptor kinase 2 of Akt/endothelial nitric-oxide synthase
signaling in human vascular endothelial cells under conditions of
hyperglycemia with high insulin levels. J Pharmacol Exp Ther.
349:199–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tomita K, Takashina M, Mizuno N, Sakata K,
Hattori K, Imura J, Ohashi W and Hattori Y: Cardiac fibroblasts:
Contributory role in septic cardiac dysfunction. J Surg Res.
193:874–887. 2015. View Article : Google Scholar
|
|
31
|
Milne JC, Lambert PD, Schenk S, Carney DP,
Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, et al: Small
molecule activators of SIRT1 as therapeutics for the treatment of
type 2 diabetes. Nature. 450:712–716. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cardaci S, Filomeni G and Ciriolo MR:
Redox implications of AMPK-mediated signal transduction beyond
energetic clues. J Cell Sci. 125:2115–2125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gillies LA and Kuwana T: Apoptosis
regulation at the mitochondrial outer membrane. J Cell Biochem.
115:632–640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsuruta F, Masuyama N and Gotoh Y: The
phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax
translocation to mitochondria. J Biol Chem. 277:14040–14047. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gardai SJ, Hildeman DA, Frankel SK,
Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL and
Henson PM: Phosphorylation of Bax Ser184 by Akt regulates its
activity and apoptosis in neutrophils. J Biol Chem.
279:21085–21095. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Franke TF, Yang SI, Chan TO, Datta K,
Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein
kinase encoded by the Akt proto-oncogene is a target of the
PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:727–736.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Franke TF, Kaplan DR, Cantley LC and Toker
A: Direct regulation of the Akt proto-oncogene product by
phosphati-dylinositol-3,4-bisphosphate. Science. 275:665–668. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Castellano E and Downward J: RAS
interaction with PI3K: More than just another effector pathway.
Genes Cancer. 2:261–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Castellano E and Santos E: Functional
specificity of ras isoforms: So similar but so different. Genes
Cancer. 2:216–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bradamante S, Barenghi L and Villa A:
Cardiovascular protective effects of resveratrol. Cardiovasc Drug
Rev. 22:169–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baur JA and Sinclair DA: Therapeutic
potential of resveratrol: The in vivo evidence. Nat Rev Drug
Discov. 5:493–506. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ota H, Tokunaga E, Chang K, Hikasa M,
Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y and Kaneki M: Sirt1
inhibitor, Sirtinol, induces senescence-like growth arrest with
attenuated Ras-MAPK signaling in human cancer cells. Oncogene.
25:176–185. 2006.
|
|
43
|
Testa JR and Tsichlis PN: AKT signaling in
normal and malignant cells. Oncogene. 24:7391–7393. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yan J, Roy S, Apolloni A, Lane A and
Hancock JF: Ras isoforms vary in their ability to activate Raf-1
and phosphoinositide 3-kinase. J Biol Chem. 273:24052–24056. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Voice JK, Klemke RL, Le A and Jackson JH:
Four human ras homologs differ in their abilities to activate
Raf-1, induce transformation, and stimulate cell motility. J Biol
Chem. 274:17164–17170. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Eisfeld AK, Schwind S, Hoag KW, Walker CJ,
Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson
GA, et al: NRAS isoforms differentially affect downstream pathways,
cell growth, and cell transformation. Proc Natl Acad Sci USA.
111:4179–4184. 2014. View Article : Google Scholar : PubMed/NCBI
|
